Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (Q38376308)

2 September 2017

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (English)

1 reference

2 September 2017

1 reference

1 reference

7

John D Hainsworth

1 reference

2 September 2017

4

Janice P Dutcher

1 reference

2 September 2017

Walter M Stadler

1

1 reference

2 September 2017

Robert A Figlin

2

1 reference

2 September 2017

David F McDermott

3

1 reference

2 September 2017

Jennifer J Knox

5

1 reference

2 September 2017

Wilson H Miller

6

1 reference

2 September 2017

Charles A Henderson

8

1 reference

2 September 2017

Jeffrey R George

9

1 reference

2 September 2017

Julio Hajdenberg

10

1 reference

2 September 2017

Tamila L Kindwall-Keller

11

1 reference

2 September 2017

Marc S Ernstoff

12

1 reference

2 September 2017

Harry A Drabkin

13

1 reference

2 September 2017

Brendan D Curti

14

1 reference

2 September 2017

Luis Chu

15

1 reference

2 September 2017

Christopher W Ryan

16

1 reference

2 September 2017

Sebastien J Hotte

17

1 reference

2 September 2017

Chenghua Xia

18

1 reference

2 September 2017

Lisa Cupit

19

1 reference

2 September 2017

Ronald M Bukowski

20

1 reference

2 September 2017

ARCCS Study Investigators

21

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

2 September 2017

1 reference

2 September 2017

116

1 reference

2 September 2017

5

1 reference

2 September 2017

1272-1280

1 reference

2 September 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Recent progress in the management of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.24864

1 reference

7 January 2021

Advanced renal cell carcinoma: current and emerging management strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Mechanisms of hypertension associated with BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.24864

1 reference

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24864

7 January 2021

Identifiers

DOI

10.1002/CNCR.24864

1 reference

2 September 2017

1 reference